The Neuroprotective Effect of the Novel Noncompetitive NMDA Antagonist, FR115427 in Focal Cerebral Ischemia in Rats | Zendy

Kiyotaka Katsuta | Zendy; Hajime Nakanishi | Zendy; Kiyoharu Shirakawa | Zendy; Keizo Yoshida | Zendy; Kiyoshi Takagi | Zendy; Akira Tamura | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Neuroprotective Effect of the Novel Noncompetitive NMDA Antagonist, FR115427 in Focal Cerebral Ischemia in Rats

Author(s) -

Kiyotaka Katsuta,

Hajime Nakanishi,

Kiyoharu Shirakawa,

Keizo Yoshida,

Kiyoshi Takagi,

Akira Tamura

Publication year - 1995

Publication title -

journal of cerebral blood flow and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.167

H-Index - 193

eISSN - 1559-7016

pISSN - 0271-678X

DOI - 10.1038/jcbfm.1995.40

Subject(s) - neuroprotection , ischemia , medicine , antagonist , nmda receptor , hypothermia , anesthesia , brain ischemia , middle cerebral artery , gerbil , excitotoxicity , stroke (engine) , glutamate receptor , pharmacology , receptor , mechanical engineering , engineering

The present study was carried out to compare the neuroprotective effect of the novel noncompetitive NMDA antagonist, FR115427, with that of (+)MK-801 in rat focal cerebral ischemia. Focal cerebral ischemia was produced by permanent occlusion of the left middle cerebral artery (MCA). Drugs were administered intraperitoneally immediately after ischemia and once a day for 6 successive days. FR115427 (10 mg/kg, i.p.) significantly improved neurologic deficit at 1 day after ischemia and reduced total infarct volume (54%) at 7 days after ischemia. Although FR115427 (10 mg/kg, s.c.) produced neuronal vacuolization similar to (+)MK-801, FR115427 did not produce adverse effects such as a loss of body weight, mortality, and hypothermia, in contrast to (+)MK-801. These results suggest that FR115427 may be useful in the treatment of stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research